After inking a related patent settlement last year, Viatris has cleared another obstacle in its quest to launch generic ...

The Delaware court ruled that Viatris’ drug does not infringe the "administered without another therapeutic agent" limitation ...

Viatris offers value with high free cash flow and dividends but faces growth challenges from legacy drug price erosion and ...

Aurobindo, Cipla and Viatris will develop, manufacture and supply long-acting injectable cabotegravir. Aurobindo, Cipla and ...

Erectile dysfunction (ED), a condition often overlooked and stigmatized in Africa due to widespread misinformation, affects ...

A recently launched video series from the Biotechnology Innovation Organization (BIO) seeks to show how biotech may be able ...

At Yahoo Finance, you get free stock quotes, up-to-date news, portfolio management resources, international market data, ...

Viatris was falling Friday after the pharmaceutical company announced that its eye inflammation treatment didn’t meet its ...

The end of the earnings season is always a good time to take a step back and see who shined (and who not so much). Let’s take ...

Viatris's phase 3 trial for pimecrolimus 0.3% in blepharitis failed to meet its primary endpoint of debris resolution after ...

Viatris Inc. closed 31.66% below its 52-week high of $13.55, which the company reached on November 25th.